Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-in-Human Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Malignancies

NCT05378425 is registered in ClinicalTrials.gov with Nectin Therapeutics Ltd as lead sponsor.

NCT NCT05378425
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05378425 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-in-Human Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Malignancies
Lead sponsor
Nectin Therapeutics Ltd
Phase
Phase 1
Overall status
Active, not recruiting
Start date
September 1, 2022
Completion date
December 31, 2026
Enrollment
90 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, cancer, locally advanced solid tumor, metastatic cancer, tumor, solid